Introduction
Fatty acid oxidation (FAO) provides the majority of energy for cardiac work. In the healthy heart $60% of the energy is provided by FAO, while the remaining energy is contributed by other substrates such as glucose. 1, 2 Shifts in the preference for fatty acids have been associated with several cardiac diseases such as heart failure and diabetic cardiomyopathy. 2 Most disease states, however, are associated with metabolic and physiologic changes that extend beyond fatty acid preference, and thus it is difficult to establish whether a shift in fatty acid use is causal or reactive, or even adaptive or maladaptive.
Changes in cardiac use of fatty acids will have to be compensated for by reciprocal changes in oxidation of other substrates. FAO is regulated by both transcriptional and post-transcriptional mechanisms, 3 but allosteric regulation of the activity of carnitine palmitoyltransferase 1 (CPT1) is thought to be a main mechanism. CPT1 performs the first step in the transport process of fatty acids into mitochondria, and its activity is considered rate limiting for FAO. 4 Acetyl-CoA carboxylase (ACC) synthesizes malonyl-CoA, a potent inhibitor of CPT1. 4, 5 Malonyl-CoA decarboxylase (MCD) catalyses the reverse reaction relieving inhibition of FAO ( Figure  1A ). Indeed, in isolated rat hepatocytes, the activity of CPT1 strongly determines FAO rates. 6 CPT1 in liver is encoded by the ubiquitously expressed Cpt1a gene. In heart and muscle, however, the majority of CPT1 is encoded by Cpt1b, a gene with a more specific tissue expression profile. CPT1B has a higher affinity for malonyl-CoA when compared with CPT1A, but the control of CPT1B on FAO flux has not been assessed directly. In fact, some investigators have debated the importance of CPT1B in determining FAO rates, because the malonyl-CoA concentration in skeletal muscle and heart greatly exceeds its IC 50 . 7, 8 In addition, the IC 50 of malonyl-CoA for CPT1B in muscle is dependent on palmitoyl-CoA concentration and assay procedure. 9 Furthermore, partial inhibition of CPT1B using pharmacological or genetic tools did not decrease FAO rates in isolated cardiomyocytes and isolated working hearts, 10, 11 which is at odds with CPT1B being rate limiting. There are, however, also strong arguments in favour of a high control of CPT1B on FAO rates. ACC2 (Acacb) knockout (KO) mice have lower cardiac malonyl-CoA levels, accompanied by an increase in FAO. 12, 13 In addition, acute pharmacological inhibition of MCD increases malonyl-CoA levels and decreases cardiac FAO. 14, 15 In summary, the role of CPT1B in cardiac metabolic homeostasis has been addressed by pharmacologic or genetic inhibition of CPT1B activity or by modulation of tissue malonyl-CoA metabolism. No studies have assessed the effects of changing the malonyl-CoA sensitivity of CPT1B. (n = 5), and Cpt1b E3A/E3A (n = 7) mice. For each genotype, the activity without malonyl-CoA was set to 100% and the activity with Triton X-100 was set to 0%. The concentration malonyl-CoA is in lM. Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. The studies that have addressed the role of CPT1B in cardiac metabolic homeostasis have limitations. The pharmacologic or genetic inhibition of CPT1B was relatively small ($50%), 10, 11 which may have allowed for compensatory mechanisms such as decreased malonyl-CoA levels or increased substrate levels to mask the effect of the perturbation. Both mechanisms were not evaluated in these studies. The consequences of modulating tissue malonyl-CoA metabolism may be pleiotropic because the functions of malonyl-CoA are not limited to regulation of FAO. Classically, malonyl-CoA is a precursor for fatty acid synthesis. In nonlipogenic tissues such as the heart, malonyl-CoA may play a role in lysine malonylation of proteins. 16, 17 These multiple roles are not only exemplified by the severe phenotypic presentation of humans and mice with MCD (MLYCD) deficiency, 18, 19 but also by the cytosolic, mitochondrial, and peroxisomal localization of MCD. 20, 21 Here we test the hypothesis that malonyl-CoA sensitivity of CPT1B is a major determinant of FAO in the heart by the generation and characterization of a novel knock in mouse model that expresses a mutant CPT1B with decreased malonylCoA sensitivity. We furthermore hypothesize that this mutation will increase in situ CPT1 activity without affecting tissue malonyl-CoA levels. These mutant mice have increased FAO rates in perfused hearts, but surprisingly also increased malonylcarnitine levels in CPT1B expressing tissues. We found small changes in cardiac function in vivo, and no cardiac hypertrophy and fibrosis. Our data illustrate the crucial role of malonylCoA-dependent inhibition of CPT1B in regulating cardiac FAO and suggest that chronic elevation of FAO has a relatively subtle impact on cardiac function.
Methods

Detailed materials and methods
Detailed materials and methods are available in the Supplementary material online.
Site-directed mutagenesis and heterologous expression of mouse CPT1A and CPT1B
The E3A mutation in Cpt1a and Cpt1b was introduced via site-directed mutagenesis. CPT1 proteins were expressed in Saccharomyces cerevisiae.
Animal studies
All animal experiments were approved by institutional review boards for animal experiments; the animal experiments committee of the Academic Medical Center (Amsterdam, the Netherlands), the local animal experimentation committee of the Canton Figure 1B ) and maintained by crossing with C57BL/6NCrl mice. Cpt1b
, and Cpt1b
E3A/E3A mice were generated via heterozygous and homozygous breeding pairs. The mice were housed at 21 ± 1 C, 40-50% humidity, and a 12-h light-dark cycle, with ad libitum access to water and standard rodent chow diet (CRM (E), SDS, UK) unless stated otherwise. Five different cohorts of male mice were used for the following experiments: (i) metabolic characterization (Cpt1b WT/WT n = 6,
Cpt1b
WT/E3A n = 5, and Cpt1b E3A/E3A n = 7, 15 weeks of age), (ii) isolated heart perfusions (Cpt1b WT/WT n = 10 and Cpt1b E3A/E3A n = 10, 25 weeks of age), (iii) in vivo magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) measurements (Cpt1b WT/WT n = 2, C57BL/ 6NCrl Charles River n = 8, and Cpt1b E3A/E3A n = 10, 12-13 weeks of age), (iv) RNA-sequencing analysis (Cpt1b WT/WT n = 4, Cpt1b
WT/E3A n = 4, and Cpt1b E3A/E3A n = 5, 13 weeks of age), and (v) mitochondrial proteomics (C57BL/6NCrl Charles River n = 10, and Cpt1b E3A/E3A n = 8, 18 weeks of age).
Mice were anaesthetized with an intraperitoneal injection of 80 or 100 mg/kg pentobarbital. For necropsy, anaesthetized mice were euthanized by exsanguination from the inferior vena cava. For the Langendorff perfusion, mice were euthanized by excision of the heart, after tracheotomy, mechanical ventilation, and in situ cannulation. Depth of anaesthesia was monitored via pain reflexes. The MRI and MRS measurements were performed under isoflurane anaesthesia (induction 3%, maintenance 1-2%, in medical air at a flow rate of 0.4 l/min). In all other circumstances, mice were euthanized by CO 2 inhalation.
Quantitative PCR and immunoblotting
Quantitative PCR and immunoblotting were performed as described in. 22 Primers are available in Supplementary material online, Table S1 .
The polyclonal antibody against CPT1B (HPA029583) was obtained from Sigma-Aldrich. Secondary antibodies goat anti-rabbit IRDye 800CW were from LI-COR Biosciences (Lincoln, NE, USA) and immunoblot images were obtained using the Odyssey infra-red imaging system (LI-COR Biosciences).
In vitro CPT activity measurements
Homogenates of mouse tissue or yeast protoplasts were used for CPT1 activity measurements. The CPT1 activity was measured as the synthesis rate of [U-
13
C]-C16:0-carnitine as described previously in. 23 Triton X-100 inactivates CPT1 thus yielding CPT2 activity. 23 CPT1 activity was calculated by subtracting CPT2 activity from the total CPT activity. 
Isolated heart perfusions and determination of the rates of glycolysis and glucose and FAO
Isolated (Langendorff) heart perfusions were performed as described previously in. 24 The distribution of isotopologues in citric acid cycle (CAC) intermediates was determined and used for the calculation of contribution of glucose and palmitate to acetyl-CoA formation for citrate synthesis, 25 and the net production of lactate and pyruvate.
MRI and MRS experiments
Cardiac function measurement using (high temporal resolution) cinematic MRI, myocardial TG measurements using 1 H MRS and cardiac energy status measurements using 31 P MRS were performed as described previously in. [26] [27] [28] [29] 2.8 RNA sequencing, differential gene expression, pathway enrichment, and transcription factor-binding analysis RNA sequencing and differential gene expression analysis were performed as described previously in. 24, 30 Outlier detection identified five samples, three of which were on one lane (see Supplementary material online, Figure S2A ). These samples were removed leaving 3 mice per genotype for differential gene expression analysis. Pathway enrichment analysis was performed using the ClueGO and CluePedia plugins in Cytoscape. 31, 32 Cut off for pathway enrichment was chosen at an adjusted P < 0.01. Iregulon was used for transcription factor-binding analysis. 33 
Histology
Cpt1b WT/WT (three females, one male, 20-25 weeks of age) and
Cpt1b
E3A/E3A hearts (two females, one male, all 17 weeks of age) were submitted for histology. Hearts were sectioned longitudinally for a fourchambered view and stained with hematoxylin and eosin (two serial sections) and trichrome.
Targeted quantitative mitochondrial proteomics
A set of 54 mitochondrial proteins were quantified in isolated mitochondria as described in.
34,35
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 or 6 (GraphPad Software, La Jolla, CA, USA). Differences were evaluated using a two-sided t test or a one-way analysis of variance with Bonferronicorrected post hoc tests. Statistical significance was set at P < 0.05.
Results
Characterization of the kinetic parameters of CPT1B with reduced malonyl-CoA sensitivity
The Glu3Ala point mutation (E3A) is known to decrease malonyl-CoA sensitivity in rat CPT1A. 36 In order to determine whether the E3A point mutation also affects malonyl-CoA sensitivity of CPT1B, we expressed mouse CPT1A and CPT1B and the E3A mutants for both isoforms in S. cerevisiae and measured their kinetic properties and IC 50 for malonylCoA in homogenates (see Supplementary material online, Table S2 ). CPT1A and CPT1B differ in their malonyl-CoA sensitivity (IC 50 = 116 vs. 0.29 mM, respectively), which is well documented. 7, 37, 38 The CPT1A and CPT1B E3A mutants had a 17-and 123-fold decrease in malonyl-CoA sensitivity, respectively. The kinetic parameters for palmitoyl-CoA and carnitine were unchanged in the E3A mutants when compared with their WT counterparts (see Supplementary material online, Table S2 ). Thus, the CPT1B E3A mutant has decreased malonyl-CoA sensitivity, but retains otherwise normal enzyme kinetics.
Generation and biochemical characterization of Cpt1b
E3A mutant mice
The p.E3A mutation was introduced into the Cpt1b gene using homologous recombination in C57BL/6N ES cells ( Figure 1B Figure 1C) , which was further confirmed by RNA sequencing (Figure 4) . To establish whether Cpt1b E3A exhibited decreased malonyl-CoA sensitivity in mice, we performed CPT activity measurements using a range of malonyl-CoA concentrations in Cpt1b WT/WT , Cpt1b WT/E3A , and Cpt1b E3A/E3A mouse heart, quadriceps muscle, and liver extracts. CPT1 activity in Cpt1b
E3A/E3A mouse hearts and quadriceps muscles had a pronounced decrease in malonyl-CoA sensitivity ( Figure 1D ). Malonyl-CoA sensitivity appeared at least partially gene dose dependent, since CPT1 activity also displayed decreased malonyl-CoA sensitivity in hearts of Cpt1b WT/E3A mice. As expected, the malonyl-CoA sensitivity of CPT1 activity in liver was not changed as this activity is catalysed by CPT1A ( Figure 1D) . Thus, the p.E3A mutation decreases malonyl-CoA sensitivity of CPT1B in heart and muscle. Table S3 ). Selected blood metabolites were also analysed in the random fed and overnight fasted state and were similar between groups (see Supplementary material online, Table S3 ). In addition, body, cardiac, and liver weights were similar in all groups (see Supplementary material online, Table S3 ). CPT1B catalyses the formation of long-chain acylcarnitines. Therefore, we determined the acylcarnitine profile of the CPT1B-expressing tissues including heart, quadriceps muscle, and brown adipose tissue, as well as of the liver (see Supplementary material online, Table S4 ). Remarkably, we observed no changes in long-chain acylcarnitine or free carnitine levels. Unexpectedly, malonylcarnitine (C3DC) was the only acylcarnitine that was increased in heart, quadriceps muscle, and brown adipose tissue of Cpt1b E3A mutant mice (see Supplementary material online, Tables S3 and   S4 ). This indicates that although malonyl-CoA metabolism was not directly modulated, the levels of malonyl-CoA are affected.
Increased selection of fatty acids for oxidation in Cpt1b
E3A mutant hearts In these experiments, the hearts were perfused with stable isotope labelled glucose or palmitate and isotopologue distribution of the cardiac CAC intermediates was used to calculate the relative contribution
WT/WT hearts (Figure 2A) , which is evident from the isotopologue distribution in the CAC intermediates (see Supplementary material online, Figure S1 ). The relative contribution of glucose oxidation was similar in Cpt1b E3A/E3A and Cpt1b WT/WT hearts ( Figure 2A , see Supplementary material online, Figure S1 ). The production of pyruvate and lactate from labelled glucose in the cardiac effluent, reflecting glycolysis, appeared higher in Cpt1b E3A/E3A hearts, but was not significant due to one outlier ( Figure 2B ).
3.5
In vivo cardiac function, lipid content, and energy status in Cpt1b E3A mutant mice
Next, we assessed LV mass, cardiac function, lipid content and energy status in vivo in Cpt1b WT/WT and Cpt1b E3A/E3A mice using MRI and MRS.
Cardiac function measurements using cinematic MRI revealed increased end-diastolic volume (EDV) and end-systolic volume (ESV) in Cpt1b
mice when compared with Cpt1b WT/WT mice, which was paralleled by a small increase in LV mass ( Table 2) . Peak ejection rate (PER) and early peak filling rate (E) were lower in Cpt1b E3A/E3A mice compared with
Cpt1b
WT/WT mice, indicating minor systolic and diastolic dysfunction, respectively. Ejection fraction (EF), stroke volume (SV), and late peak filling rate (A) were similar between groups ( Table 2) .
Myocardial lipid content was measured in the myocardial septum using 1 H MRS ( Figure 3A) by quantifying all lipid-associated peaks (Peaks 1 and 5-10 in Figure 3B ) and was similar between Cpt1b E3A/E3A and
WT/WT mice ( Figure 3C ). In addition, we employed 31 P MRS to assess the cardiac energy status in vivo. A typical cardiac 31 P MR spectrum contains a phosphocreatine (PCr) peak originating from myocardium, a 2, 3-diphosphoglycerate peak from blood in the LV lumen (which obscures the inorganic phosphate peak from myocardium), and c-ATP, a-ATP, b-ATP peaks from mainly myocardium with a minor contamination from blood ( Figure 3D and E) . The in vivo PCr to ATP ratio (PCr/ATP ratio), which is a measure of in vivo cardiac energy status, was 23% lower in Cpt1b E3A/E3A mice as compared with Cpt1b WT/WT mice (P < 0.05, Figure 3F ).
Transcriptional adaptations in the heart of Cpt1b
E3A mutant mice
In order to explore transcriptional adaptations to increased FAO in hearts of Cpt1b E3A mutant mice, we performed RNA-sequencing analysis Figure S2B ). This result provides further evidence that there is a gene dose effect of the Cpt1b E3A mutation. Limma methodology detected fewer DEGs, but all of these were also found by DESeq2 (see Supplementary material online, Figure S2B) . Overall, the fold changes in the DEGs were small ranging from 0.61 to 1.35 indicating the genetic perturbation has a small impact on the transcriptome ( Figure 4A) . Canonical pathway enrichment analysis of the 158 DEGs revealed a highly significant enrichment of genes involved in FAO ( Figure 4B , see Supplementary material online, Table S6 ). All these FAO genes were down regulated indicating that transcriptional adaptation in Cpt1b
hearts is aimed at limiting FAO. Collagen and elastic fibre formation were also enriched with gene expression increased in Cpt1b hearts, however, did not reveal significant microscopic lesions or fibrosis (Histology report attached to the Supplementary material online). We used iRegulon 33 in order to identify 'regulons' using motif discovery in the DEGs identified in Cpt1b E3A/E3A mice. A regulon is defined as consisting of a transcription factor and its predicted direct transcriptional targets, which within their cis-regulatory control elements contain associated transcription factor-binding sites. The top transcription factorbinding site found enriched in the DEGs was for elements related to peroxisome proliferator-activated receptor gamma (PPARc) ( Figure 4C ).
There is considerable motif similarity between nuclear hormone receptor response elements and that of PPARs in particular ( Figure 4C ). PPARs WT/WT n = 10 and Cpt1b E3A/E3A n = 9. *P < 0.05 in unpaired t test. heterodimerize with retinoid X receptor and are known to bind a direct repeat of a nuclear receptor-binding site (AGGTCA) spaced by one nucleotide ( Figure 4D) . It is well established that PPARa and PPARb play important roles in the regulation of the expression of FAO genes in the heart. Indeed, many of the DEGs are established PPAR target genes ( Figure 4E ). Therefore the DEGs most likely reflect a decrease in activation of PPARa and/or PPARb in Cpt1b E3A/E3A hearts. Other enriched motifs represent binding sites for the Sp-and Tceal-family of transcription factors ( Figure 4C) . In order to explore post-transcriptional changes adaptations to increased FAO, we performed a targeted proteomic analysis of mitochondria isolated from Cpt1b
WT/WT and Cpt1b E3A/E3A hearts. Analysed proteins include mitochondrial and nuclear encoded subunits of the oxidative phosphorylation complexes, all enzymes involved in the TCA cycle and FAO, pyruvate dehydrogenase, the relevant mitochondrial substrate transporters, several antioxidant enzymes, and uncoupling proteins (see Supplementary material online, Table S7 ). Unexpectedly, CPT1B was the only protein that significantly changed. The protein concentration in Cpt1b E3A/E3A heart mitochondria was only 25% of
Cpt1b
WT/WT levels. We were not able to confirm the observed small transcriptional downregulation of FAO genes at the protein level, nor did we find changes in any of the other tested proteins.
Post-transcriptional regulation of CPT1B protein levels in response to changes in FAO flux
The targeted proteomic analysis showed a pronounced decrease in CPT1B protein levels in Cpt1b E3A/E3A heart mitochondria. This was further confirmed by CPT1 activity assays in heart and quadriceps muscle of Cpt1b E3A/E3A mice ( Figure 5A ). This decrease in CPT1 activity in Cpt1b E3A/E3A mice is due to lower CPT1B protein levels, and is not explained by lower expression of mutant Cpt1b mRNA ( Figure 5B ). These data show that CPT1 activity and CPT1B protein expression were decreased in parallel with the decreased malonyl-CoA sensitivity. Next, we tried to address whether the E3A mutation makes the CPT1B protein inherently unstable or whether the decrease in CPT1B protein levels reflects a regulatory mechanism aimed at limiting the enhanced FAO. Previous work demonstrated that rat CPT1A and CPT1A
E3A have similar steady-state protein levels upon expression in Figure  S3 ). In order to address the hypothesis that CPT1B protein and activity levels are subject to post-transcriptional regulation, we determined CPT1B protein level in two additional transgenic mouse models; the cardiac-specific ACC2 KO (ACC2 HKO) and the MCD KO. 12, 39 Hearts of ACC2 HKO mice have low cardiac malonyl-CoA levels and as a consequence increased FAO and as such partially resemble hearts of Cpt1b E3A/E3A mice. Similar to Cpt1b E3A/E3A hearts, the hearts of ACC2
HKO mice displayed a decrease in CPT1B protein levels in the absence of changes in Cpt1b mRNA levels ( Figure 5C ). The reverse occurred in MCD KO mice, which have high cardiac malonyl-CoA levels and inhibited FAO. In the hearts of these mice, we observed an increase in CPT1B protein levels, again in the absence of changes in Cpt1b mRNA levels ( Figure 5D ). Combined these data suggest the existence of a post-transcriptional regulatory mechanism affecting CPT1B protein levels in heart in response to changes in FAO.
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Discussion
Here, we report the generation and characterization of the Cpt1b E3A knock in mouse model, in which CPT1B has a reduced sensitivity to malonyl-CoA. FAO was 1.9-fold increased in isolated perfused hearts from Cpt1b E3A/E3A mice when compared with hearts of Cpt1b WT/WT mice, which is consistent with the proposed allosteric regulation of CPT1B by malonyl-CoA. Thus under physiological conditions, malonylCoA is able to effectively limit the cardiac FAO rate. Our results demonstrate that malonyl-CoA-dependent inhibition of CPT1B is crucial for the regulation of cardiac FAO and further supports the hypothesis that CPT1B is rate limiting for FAO at least in the heart. Unexpectedly hearts of Cpt1b E3A/E3A displayed increased malonylcarnitine levels and decreased CPT1B protein levels. Modulation of malonyl-CoA levels, which are reflected by malonylcarnitine levels, is a well-established mechanism to control FAO. The post-transcriptional regulation of CPT1B protein levels is a phenomenon not previously recognized to contribute to the control of FAO. The Cpt1b E3A knock in mouse is the first reported animal model that allows for the direct study of the role of malonyl-CoA-dependent inhibition of CPT1B. Other mouse models of increased or decreased cardiac FAO have been reported, but are based on the modulation of malonylCoA levels (ACC2 and MCD KO mice, respectively). We had hypothesized that malonyl-CoA levels would be unaffected in the Cpt1b E3A knock in mouse. However, opposite to our prediction, we found increased malonylcarnitine concentrations in CPT1B expressing tissues of Cpt1b E3A/E3A mice. It is known that increased levels of malonyl-CoA lead to increased malonylcarnitine. 40 Our enzyme assays did not provide evidence that the CPT1B E3A variant itself directly contributed to the formation of malonylcarnitine. Therefore activation of CPT1B by decreasing its malonyl-CoA sensitivity, most likely increases malonyl-CoA levels through an indirect mechanism involving changes in ACC and/or MCD activity.
The role of CPT1B as rate limiting enzyme for cardiac FAO was previously addressed using pharmacological or genetic tools. Partial inhibition of CPT1B did not decrease FAO in isolated cardiomyocytes and a heterozygous deletion of Cpt1b did not decrease FAO in isolated working hearts, 10, 11 both experiments arguing against CPT1B being rate limiting.
The decrease in CPT1B activity, however, was relatively small ($50%) 10, 11 and could have been counteracted by decreased malonylCoA levels. Both studies did not assess cardiac malonyl-CoA or malonylcarnitine levels. Our data suggest that direct modulation of CPT1B activity can affect tissue malonyl-CoA levels. The Cpt1b E3A knock in mouse is most similar to whole body and cardiac-specific ACC2 KO mouse models. 12, 13 Indeed all these models are characterized by increased FAO in isolated heart perfusions. Glucose oxidation ex vivo was increased in the whole body ACC2 KO, 13 and decreased in the cardiac-specific ACC2 KO. 12 We observed similar glucose oxidation between Cpt1b E3A/E3A and Cpt1b WT/WT hearts.
This implies that oxidation of other unlabelled endogenous or exogenous substrates such as lactate/pyruvate in the perfusion medium will be decreased to accommodate for the increased FAO. We assessed cardiac function ex vivo in perfused hearts and in vivo using MRI. Ex vivo Cpt1b E3A/E3A hearts have a slightly increased RPP and MVO 2 due to an increased HR. The mechanism underlying this increased HR is unclear, but cardiac metabolism has been associated with HR in a study of different inbred mouse strains. 41 The in vivo MRI measurement did not reveal differences in HR, but showed minor systolic and diastolic dysfunction in Cpt1b E3A/E3A mice. We believe that the observed small decreases in PER and early peak filling rate are related to the small increase in LV weight of Cpt1b E3A/E3A mice used for the MRI analysis. This increased LV weight was not reproduced upon analysis of total ventricular weight during necropsy in other cohorts and is therefore unrelated to the Cpt1b E3A genotype. Although myocardial lipid accumulation is absent and the decrease in PCr/ATP ratio is relatively small in Cpt1b
hearts, the combination with diastolic dysfunction is reminiscent of diabetic cardiomyopathy. 26 Transcriptional profiling also revealed a small but coordinated decrease in the expression of genes involved in FAO. Unbiased transcriptional profiling was not performed in the ACC2 KO mouse models, but a down-regulation of PPARa signalling was noted for the whole body ACC2 KO. 13 Indeed, motif discovery in the promoter region of the mice. Cpt1b mRNA expression levels were similar between all genotypes implying that the decrease of CPT1B protein levels is a post-transcriptional event. Amino acid substitutions may render a protein unstable, but the WT and E3A mutant CPT1B expressed equally well in yeast suggesting that CPT1B E3A is not inherently unstable. As the E3A mutation is expected to affect the malonyl-CoA binding site, we speculate that conformational changes induced by malonyl-CoA binding may be involved in a post-transcriptional mechanism regulating CPT1B protein levels. We tested this hypothesis in heart samples from cardiac-specific ACC2 KO and MCD KO mice. Similar to Cpt1b E3A/E3A hearts, CPT1B protein was decreased in ACC2 KO hearts, but Cpt1b mRNA levels were not changed. The fold change in CPT1B protein observed in ACC2 KO hearts was comparable to the change in Cpt1b E3A/E3A hearts. MCD KO hearts showed the opposite phenomenon, CPT1B protein was increased, again without any changes in Cpt1b mRNA levels. These data suggest that CPT1B protein levels are regulated in response to malonylCoA concentration via an as of yet undiscovered pathway. We propose that CPT1B without malonyl-CoA bound, which conformation is mimicked by CPT1B
E3A
, is more susceptible to degradation. It is tempting to speculate that regulation of flux through CPT1B is not only determined by malonyl-CoA dependent inhibition, but also by malonyl-CoA dependent regulation of protein levels. Additional studies will be needed to address this further.
